Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
Study identifier:D0475C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects after Oral Multiple Ascending Doses
Medical condition
Pain
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2066, Placebo
Sex
All
Actual Enrollment
110
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 Nov 2008
Study Completion Date: 01 Nov 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Oral solution. | Drug: AZD2066 Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel. Other Name: AZD2066 |
| Placebo Comparator: 2 Oral solution | Drug: Placebo Administered orally as a solution once per day on day 1, and then day 3 through to day 12. |
Contacts
Investigators
Principal Investigator
Bo Fransson
AstraZeneca R&D SödertäljeMedical Science, CPU C2:84Karolinska University Hospital HuddingeSE-141 86 Stockholm, Sweden
